Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.

Autor:	Seabloom DE; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Galbraith AR; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Haynes AM; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Fujita AS; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Antonides JD; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Wuertz BR; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America.; Department of Otolaryngology, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Steele VE; Division of Cancer Prevention, National Cancer Institute9609 Medical Center Drive, Room 5E454, Rockville, MD 20850, America., Ondrey FG; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America.; Department of Otolaryngology, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America., Wattenberg LW; Masonic Cancer Center, University of MinnesotaMMC396, 420 Delaware St. SE, Minneapolis, MN 55455, America.
Jazyk:	angličtina
Zdroj:	American journal of translational research [Am J Transl Res] 2018 Mar 15; Vol. 10 (3), pp. 875-880. Date of Electronic Publication: 2018 Mar 15 (Print Publication: 2018).
Abstrakt:	Talactoferrin alpha is a promising non-toxic solid tumor cancer agent that met with success in the treatment of early-stage lung cancer clinically in humans. It is well-tolerated, anddendritic cell-stimulation is a target. We tested the efficacy of this agent in a chemoprevention setting in A/J mice. All groups received benzo[a]pyrene (B[a]P) by oral gavage in three doses of 3 mg/kg body weight over the course of one week. Animals were then randomized into 5 groups of 24 mice per group based on weight. Experimental diets oftalactoferrin alpha (Agennix Inc., Indianapolis, IN), at 1.40% and 0.42% of the diet, were started one week or eight weeks after the last dose of B[a]P. Animals were continued on the feeding schedule, weighed weekly, and monitored for toxicity. The study was concluded 16 weeks after administration of B[a]P. The agent was well-tolerated for the duration of the experiment and there was no observable toxicity or weight change. The average number of adenomas per animal was 14.04 ± 0.93 (N=24) in the control group, 18.14 ± 1.45 (N=22) in the early low-dose group, 16.70 ± 1.30 (N=23) in the late low-dose group, 15.09 ± 1.41 (N=23) in the early high-dose group and 14.46 ± 1.21 (N=24) in the late high-dose group. We conclude talactoferrinalpha is well-tolerated. However, it did not inhibit carcinogenesis at a dose of 1.4% or 0.42% of the diet, which equates to human doses of 1.12 g/kg/day or 0.336 g/kg/day. Competing Interests: None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu